Greetings Aras:
I believe you are searching for Non-Hodgkins Lymphoma Type B and the
most concise and easiest to understand explanation is located at
http://www.lymphoma.org/site/PageServer?pagename=NHLnew. This is the
site of the Lymphoma Research Foundation.
As explained there,
"What Is Non-Hodgkin's Lymphoma?
"Non-Hodgkin's lymphoma (NHL) is the most common cancer of the
lymphatic system. Since the early 1970's, incidence rates for
non-Hodgkin's lymphoma have nearly doubled. The overall five-year
survival rate is only 55%. Of the 500,000 Americans with lymphoma,
332,000 have this form. Each year, approximately 53,400 new cases of
NHL will be diagnosed and 23,400 Americans will die from the disease.
"NHL is not a single disease, but rather a group of several closely
related cancers that affect the lymphatic system, which is part of the
immune system.
"NHL is broadly divided into two major groups: B-cell lymphoma (which
develops from abnormal B-lymphocytes, which is most common), and
T-cell lymphomas (which develop from abnormal T-lymphocytes).
Lymphocytes are a type of white blood cell that helps the body fight
infections. B cells develop into plasma cells that produce antibodies
to fight infections, while T-cells attack foreign invaders (bacteria,
viruses, cells, etc.) directly."
The site also addresses:
How Do Non-Hodgkin's Lymphomas Develop?
What Are The Warning Signs?
What Are The Risk Factors?
How Is NHL Treated?
What's New In Research?
The page was revised in March of 2003 so the information is recent and
I found it to be the most comprehensive NHL B explanation in layman's
terms. I'm not able to reproduce the entire text here due to
copyright guidelines.
*************
Other recent news on NHL B-cell (type B) may be found at
http://www.bloodline.net/stories/storyReader$2304 in the article
titled "Radioimmunotherapy for B Cell Non-Hodgkins Lymphoma":
"IDEC Pharmaceuticals Corporation has announced the final results of
two pivotal trials of Zevalin(TM) (Ibritumomab Tiuxetan), an
investigational radioimmunotherapy, during oral presentations at the
42nd Annual Meeting of the American Society of Hematology (ASH).
"Thomas E. Witzig, M.D. of the Mayo Clinic, Rochester, MN, delivered
an oral presentation of a Phase III randomized, controlled study of
143 patients with relapsed or refractory low grade, follicular, or
CD20-positive transformed B-cell non-Hodgkins lymphoma (NHL). He noted
that the Zevalin combined with Rituxan arm of the study showed an
overall response rate (ORR) of 80 percent, compared to the Rituxan(R)
(Rituxumab) alone control arm, which showed an overall response rate
of 56 percent."
Please visit the link to read the entire article.
************
Should you require clarification of any of the links or information I
have provided, please request it and I will be happy to respond.
SEARCH STRATEGY:
non hodgkins lymphoma type b
non hodgkins lymphoma b-cell |
